(ADDV-B) ADDvise Group B - Ratings and Ratios

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0007464862

ADDV-B: Laboratory Equipment, Medical Furniture, Orthopedic Implants, Stents, Surgical Tables

ADDvise Group AB (publ) supplies equipment to healthcare and research facilities in private and public sectors in Sweden, rest of Europe, North America, South America, Asia, and internationally. The Lab business unit provides laboratory furnishings, ventilation, climate/clean rooms, and laboratory equipment to pharmaceutical and life science industries. The Healthcare business unit develops and supplies medical equipment, pharmaceuticals, and consumables in areas, such as urology, gynecology, emergency care, and surgery. In addition, it manufactures and sells surgical tables, as well as offers cables, connectors, and wires. Further, the company offers customized solutions for the rental and sale of laboratory and medical equipment for clinical studies; designs and delivers customized cleanrooms, climate rooms, laboratory furniture, air conditioning systems, ventilated protective products, and equipment; distributes medical devices, including continuous glucose monitors and insulin pumps; orthopaedic solutions, including implants, instruments, and technologies; and develops software and instruments to quantify patient mobility, pain, and muscle strength. Additionally, it distributes healthcare and industrial ultrasound devices for healthcare and industrial applications, such as NDT inspections; operates a mail-order pharmacy; develops, manufactures, and markets over-the-counter generic drugs for pain management, coughs, colds, allergies, sinus infections, and urological conditions; products and software to streamline the monitoring of vital signs in patients in long-term care and nursing homes; and develops, manufactures, and markets colorimetric CO2 indicators used in healthcare to monitor breathing in respiratory and emergency care. The company was formerly known as ADDvise Lab Solutions AB (publ). ADDvise Group AB (publ) was incorporated in 1989 and is headquartered in Stockholm, Sweden. Web URL: https://www.addvisegroup.se

Additional Sources for ADDV-B Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ADDV-B Stock Overview

Market Cap in USD 68m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Sub-Industry Life Sciences Tools & Services
IPO / Inception

ADDV-B Stock Ratings

Growth 5y 47.6%
Fundamental 39.0%
Dividend 1.0%
Rel. Strength Industry -2502
Analysts -
Fair Price Momentum 2.75 SEK
Fair Price DCF 2.46 SEK

ADDV-B Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y -100.00%
Payout Consistency 1.0%

ADDV-B Growth Ratios

Growth Correlation 3m -84.8%
Growth Correlation 12m -96.2%
Growth Correlation 5y 68%
CAGR 5y 31.05%
CAGR/Mean DD 5y 1.16
Sharpe Ratio 12m -2.41
Alpha -100.29
Beta 0.77
Volatility 57.11%
Current Volume 439.8k
Average Volume 20d 476.7k
What is the price of ADDV-B stocks?
As of January 22, 2025, the stock is trading at SEK 2.72 with a total of 439,843 shares traded.
Over the past week, the price has changed by -14.35%, over one month by -21.87%, over three months by -54.67% and over the past year by -80.47%.
Is ADDvise Group B a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, ADDvise Group B (ST:ADDV-B) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 39.00 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ADDV-B as of January 2025 is 2.75. This means that ADDV-B is currently overvalued and has a potential downside of 1.1%.
Is ADDV-B a buy, sell or hold?
ADDvise Group B has no consensus analysts rating.
What are the forecast for ADDV-B stock price target?
According to ValueRays Forecast Model, ADDV-B ADDvise Group B will be worth about 3 in January 2026. The stock is currently trading at 2.72. This means that the stock has a potential upside of +9.19%.
Issuer Forecast Upside
Wallstreet Target Price 8.7 219.9%
Analysts Target Price - -
ValueRay Target Price 3 9.2%